IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 320 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $978,508 | +56.5% | 21,572 | +41.5% | 0.00% | 0.0% |
| Q2 2023 | $625,420 | +28.4% | 15,243 | +11.8% | 0.00% | 0.0% |
| Q1 2023 | $487,208 | -3.9% | 13,632 | +1.5% | 0.00% | 0.0% |
| Q4 2022 | $507,176 | -17.4% | 13,428 | -3.3% | 0.00% | 0.0% |
| Q3 2022 | $614,000 | +30.4% | 13,892 | +9.1% | 0.00% | 0.0% |
| Q2 2022 | $471,000 | -0.2% | 12,729 | -0.2% | 0.00% | 0.0% |
| Q1 2022 | $472,000 | +2.6% | 12,758 | -15.6% | 0.00% | 0.0% |
| Q4 2021 | $460,000 | -8.0% | 15,116 | +1.3% | 0.00% | 0.0% |
| Q3 2021 | $500,000 | -5.8% | 14,915 | +12.0% | 0.00% | 0.0% |
| Q2 2021 | $531,000 | -73.3% | 13,320 | -69.8% | 0.00% | -75.0% |
| Q1 2021 | $1,986,000 | -0.9% | 44,179 | +24.7% | 0.00% | 0.0% |
| Q4 2020 | $2,004,000 | +19.0% | 35,440 | -0.1% | 0.00% | 0.0% |
| Q3 2020 | $1,684,000 | +48.1% | 35,487 | +84.0% | 0.00% | +33.3% |
| Q2 2020 | $1,137,000 | +24.9% | 19,286 | +0.2% | 0.00% | 0.0% |
| Q1 2020 | $910,000 | -28.5% | 19,246 | -8.6% | 0.00% | -25.0% |
| Q4 2019 | $1,272,000 | -8.8% | 21,051 | -9.6% | 0.00% | -20.0% |
| Q3 2019 | $1,395,000 | -4.9% | 23,285 | -1.9% | 0.01% | 0.0% |
| Q2 2019 | $1,467,000 | -20.1% | 23,733 | +4.9% | 0.01% | -28.6% |
| Q1 2019 | $1,837,000 | +23.9% | 22,627 | -17.5% | 0.01% | +16.7% |
| Q4 2018 | $1,483,000 | +8.0% | 27,435 | +3.1% | 0.01% | +20.0% |
| Q3 2018 | $1,373,000 | +35.7% | 26,618 | +9.5% | 0.01% | +25.0% |
| Q2 2018 | $1,012,000 | -3.1% | 24,298 | +2.6% | 0.00% | 0.0% |
| Q1 2018 | $1,044,000 | -18.2% | 23,687 | -6.6% | 0.00% | -20.0% |
| Q4 2017 | $1,276,000 | -1.3% | 25,366 | -0.5% | 0.01% | -16.7% |
| Q3 2017 | $1,293,000 | -4.1% | 25,503 | -3.8% | 0.01% | -14.3% |
| Q2 2017 | $1,348,000 | +24.8% | 26,499 | -1.3% | 0.01% | +16.7% |
| Q1 2017 | $1,080,000 | -11.2% | 26,856 | +5.7% | 0.01% | -14.3% |
| Q4 2016 | $1,216,000 | +26.5% | 25,414 | -3.1% | 0.01% | +16.7% |
| Q3 2016 | $961,000 | +56.0% | 26,215 | -1.0% | 0.01% | +50.0% |
| Q2 2016 | $616,000 | -25.7% | 26,467 | +29.3% | 0.00% | -33.3% |
| Q1 2016 | $829,000 | -42.1% | 20,476 | -13.6% | 0.01% | -50.0% |
| Q4 2015 | $1,432,000 | – | 23,693 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |